browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
5e32dcd2-9a08-4389-82dc-bae0706f356c
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 18:22:46
Income (reported)
Expenses (reported)
$50,000
Expenses method
C
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS

Contact
JEANNE TUERK
Phone
+1 800-822-6637
Address
zip:60018, city:ROSEMONT, state:IL, street:9700 W. BRYN MAWR AVENUE
Client

AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS

State
IL
Country
US
Government-entity client
false
Effective date
2007-07-25
Issues lobbied + lobbyists (4)

INS — Insurance

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

EDU — Education

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Comments on the Reimagining and Improving Student Education Notice of Proposed Rulemaking; RIN 1840-AD98

Lobbyists:

Government entities lobbied: Education, Dept of; HOUSE OF REPRESENTATIVES; SENATE

MMM — Medicare/Medicaid

Support for legislative efforts to provide long term reform to the Medicare physician payment system as well as repeal the 2.5 precent efficiency cut scheduled for CY 2026. Comments in response to the proposed rule, Patient Protection and Affordable Care Act (ACA); Notice of Benefit and Payment Parameters for 2027 that opposes reinstating the prohibition on non-pediatric dental services as an essential health benefit.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.